TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius ...

An experimental protein-degrading drug from Kymera Therapeutics appeared safe and able to affect its intended target in an early-stage clinical trial, leading shares in the biotechnology company to ...

Kymera Therapeutics, Inc. KYMR reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss ...

Kymera is a clinical-stage biotech that specializes in a mechanism known as targeted protein degradation in its medicines. On Tuesday, the company delivered encouraging news from the laboratory, ...

Williams was the featured speaker in the opening session of the Society of Lab Automation and Screening (SLAS), which is being held this week in Boston. Williams is an experienced biopharma scientist, ...

Shares of Kymera KYMR have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe. This ...

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

Gizmag first met garage inventor Jason Woods back in 2011. Since then the Kymera jet-powered body board has been evolving into what is now a nearly production-ready machine complete with official ...